Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ACET
SELLAdicet Bio, Inc. · Healthcare · United States · $73M · Avg Vol: $750K/d
COMPANY DESCRIPTION
Adicet Bio, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic gamma delta T-cell therapies for cancer and autoimmune diseases. The company's proprietary platform engineers off-the-shelf gamma delta T-cells with chimeric antigen receptors (CARs) to enhance tumor targeting and durability. Adicet occupies a highly specialized niche in the cellular immunotherapy landscape, leveraging the innate and adaptive immune properties of gamma delta T-cells.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.0M | 0 | 0 | 0 | — | — | — | 42.8M | 11.4% |
| EPS | -7.81 | -15.32 | -21.28 | -16.95 | — | -13.87 | -8.80 | -3.49 | — |
| Shares | 9.3M | 9.3M | 5.2M | 9.6M | +2.6% | 9.3M | — | — | — |
| Debt | 21.0M | 20.9M | 17.2M | 14.7M | -11.2% | 13.9M | — | — | — |
| Equity | 292.3M | 170.2M | 186.6M | 159.2M | -18.3% | — | — | — | — |
| Op CF | -44.8M | -93.7M | -92.4M | -95.2M | — | -91.3M | — | — | — |
| Inv CF | -16.8M | -4.5M | -119.2M | 2.4M | — | — | — | — | — |
| Fin CF | 41.5M | 0.2M | 111.3M | 75.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ACET are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ACET | Adicet Bio, Inc.(you) | $73M | 21 | SELL |
| PLRX | Pliant Therapeutics, Inc. | $67M | 18 | STRONG SELL |
| PMVP | PMV Pharmaceuticals, Inc. | $66M | 25 | SELL |
| 4875.T | MediciNova, Inc. | $62M | 18 | STRONG SELL |
| OSTX | OS Therapies Incorporated | $68M | 16 | STRONG SELL |
| PTHS | Pelthos Therapeutics Inc. | $90M | 24 | SELL |
| ACRV | Acrivon Therapeutics, Inc. | $68M | 14 | STRONG SELL |
| ATRA | Atara Biotherapeutics, Inc. | $71M | 29 | SELL |
| VRCA | Verrica Pharmaceuticals Inc. | $86M | 16 | STRONG SELL |
| XBIT | XBiotech Inc. | $69M | 29 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%